{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33","upperLimit":"63","value":"48"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"description":"Percentage of patients who were progression free at 4 years. The 4-year progression free rate was estimated using the Kaplan Meier method.\n\nRelapse was assessed by investigator according to Revised Response Criteria for Malignant Lymphoma. Progression required a 25% increase of previous area of gadolinium enhancement, appearance of new areas of T1 gadolinium enhancement or new appearance of malignant cells in the spinal fluid or new tumor appearance in other sites of the body","dispersionType":"95% Confidence Interval","groups":[{"description":"Induction Cycles 1-3: Methotrexate 8gm/m\\^2 days 1 \\& 15; Leucovorin 100 mg/m\\^2 days 2 \\& 16; Rituximab 375 mg/m\\^2 days 3, 10, 17 \\& 24 of cycle 1, days 3 \\& 10 of cycle 2; Temozolomide 150 mg/m\\^2/day PO days 7-11\n\nInduction Cycle 4: Temozolomide 150 mg/m\\^2/day PO days 7-11; Methotrexate 8gm/m\\^2 day 15; Leucovorin 100 mg/m\\^2 day 16\n\nConsolidation Cycle 5: Methotrexate 8gm/m\\^2 days 1; Leucovorin 100 mg/m\\^2 days 2; Temozolomide 150 mg/m\\^2/day PO days 7-11\n\nConsolidation Cycle 6: Cytarabine 2 g/m\\^2 (x 8 doses) days 1-4; Etoposide 5 mg/kg (x 8 doses) days 1-4; G-CSF 5 mcg/kg/day or GM-CSF 250 mcg/m\\^2/day starting day 14 until ANC recovers (\\>= 500 for 2 consecutive days or \\>= 1500 for one day)","id":"OG000","title":"Intensive Combination Chemo & Immunotherapy"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"4 years","title":"4 Year Progression Free Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}